{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-116762","form_type":"8-K","ticker":"DERM","cik":"0001867066","company_name":"Journey Medical Corp","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.180845+00:00","generated_at":"2026-05-30T02:16:11.211022+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Journey Medical Q3 2024 revenue $14.6M, net loss $2.4M; Emrosi FDA approved for rosacea","bullets":["FDA approved Emrosi (minocycline HCl ER 40 mg) for rosacea in adults; launch expected late Q1/early Q2 2025.","Net product revenues $14.6M, down 4% YoY; Qbrexza sales up 29% to $7.6M.","Net loss $2.4M ($0.12/sh) vs net income $16.8M ($0.91/sh) in Q3 2023 (included $19M license payment).","Adjusted EBITDA $0.3M ($0.01/sh) vs $20.8M ($1.13/sh) in Q3 2023.","Gross margin improved to 63.9% from 57.9% due to lower inventory charges and royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-116762","json":"https://secwatch.observer/filing/0001104659-24-116762.json","markdown":"https://secwatch.observer/filing/0001104659-24-116762.md","text":"https://secwatch.observer/filing/0001104659-24-116762.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867066/000110465924116762/0001104659-24-116762-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867066/000110465924116762/tm2428053d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:16:11.211022+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}